Is Janoshik Analytical legitimate?
Janoshik is a legitimate, established specialist testing laboratory and has the strongest visible operating record among the niche peptide labs reviewed by PeptidePrices. No ISO/IEC 17025 accreditation was confirmed, so that institutional credential should not be implied.
Main limitation: Formal accreditation, exact facility location, and reconciliation of legal-entity naming remain unresolved.
Operator and accreditation
Operating identity
Founder Peter Magic describes the operation as beginning in 2012–2013, initially in Slovakia. The official team also names Edita Prokešová and manager Jakub Dobrík, and company materials describe more than 35 specialists. Public records and materials vary between Janoshik s.r.o., Janoshik Ltd., and brand-only usage; the current Czech entity dates to 2022.
Accreditation scope
No current ISO/IEC 17025 certificate and scope was found. A veterinary-regulator acknowledgment hosted by Janoshik confirms a statutory notification, not laboratory competence accreditation.
Capabilities and submissions
The public catalog covers peptides, PEDs, SARMs, steroids, and harm-reduction testing. A 2026 lab tour shows QR-coded intake and chain-of-custody tracking, multiple HPLC systems, LC-MS, NMR, CHNS, microbalances, refrigerated sample storage, and positive, negative, and environmental controls for sterility. Routine turnaround was described as five to six working days, while sterility requires its full incubation period.
Accepts samples submitted directly by customers.
Review findings
Who operates Janoshik
Founder Peter Magic dates the operation to roughly 2012–2013, initially in Slovakia. Current materials identify a named Czech team that includes Magic, Edita Prokešová, and manager Jakub Dobrík, while a company presentation describes more than 35 specialists. The current Czech entity dates to 2022, so the entity age and the operating history should be stated separately.
That combination—a named founder, a decade-plus service history, identifiable management, public pricing, and years of recurring reports—is stronger practical identity evidence than most specialist peptide laboratories publish.
What the 2026 laboratory tour shows
The June 2026 full laboratory tour shows a multi-room analytical facility with several HPLC systems, LC-MS, NMR, CHNS elemental analysis, microbalances, sample preparation areas, refrigerated storage, and a separate microbiology workflow. Staff described five people working on unpacking and intake, QR-coded sample tracking, and retention of peptide samples for roughly 12 weeks.
The tour states that the laboratory handled about 15,000 samples in the preceding month and sometimes received more than 1,000 samples in a day. Those are first-party volume claims shown during a third-party tour, not independently audited production totals, but they are consistent with the scale of Janoshik's public report footprint.
How the peptide workflow is described
Janoshik describes HPLC-UV for purity and LC-MS for identity, with separate services for net content and additional panels. Its broader menu includes NMR, CHNS, endotoxin, sterility, heavy metals, and other harm-reduction testing. The exact certificate controls: an advertised capability does not mean every report includes that panel.
For sterility work, the tour shows positive, negative, and environmental controls and describes a 14-day incubation before a passing result is issued. Routine analytical turnaround was described as roughly five to six working days at the time of the tour. A 2025 interview described peptides as 70% to 80% of the laboratory's work and approximately 100 peptide tests per day at that earlier point.
Why Janoshik has the strongest niche-lab record in this review
Janoshik combines long operating history, identifiable leadership, transparent prices, visible instrumentation, public verification, large report recurrence, and use by independent group-testing programs. Public datasets retain failed results alongside passes, which is more informative than a vendor library containing only favorable certificates.
The important limits are equally specific. No ISO/IEC 17025 accreditation was confirmed, a public report proves what Janoshik published rather than who selected the sample, and even a valid task-number and unique-key match does not connect a purchased vial to the tested material without custody evidence. A reported 2026 data-security incident is an operational-security issue and should not be converted into a claim about analytical validity.
Community consensus is not proficiency testing. A verified Janoshik report establishes issuer identity, not vendor batch custody.
